Looking to fill several positions: Oncology, Infectious Diseases, Clinical Coordinator, Clinical Pharmacist days, Anticoagulation. JOB DESCRIPTION: Collaborates with departmental and patient care lead...

A study of patients, at the Christie Hospital, Manchester, has shown that the decision to fund patient care depends more on where the patient lives, than the patient's health circumstances, raising public concern regarding a "postcode lottery" since each decision is made solely by the patients' local Primary Care Trust (PCT). The findings of this study are published in a letter to Clinical Oncology (http://www.elsevier.

A new study provides the best evidence to date that a psychological intervention program designed for breast cancer patients not only improves their health - it actually increases their chance of survival. Researchers at Ohio State University's Comprehensive Cancer Center found that patients participating in an intervention program reduced their risk of dying of breast cancer by 56 percent after an average of 11 years.

According to new research published in the November issue of Archives of Surgery, women who live in wealthier communities with lower population densities and a larger proportion of college-educated individuals are more likely to have immediate breast reconstruction after mastectomy. Every year in the Unites States, breast cancer affects 134 of every 100,000 women.

The risk of non-AIDS cancer is higher for individuals infected with HIV than for the general population, according to a meta-analysis presented here at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research. Compared with the general population, the risk for non-AIDS cancers was 2.3 times higher for men with HIV and 1.5 times greater for women with HIV.

Researchers in the US and The Netherlands have discovered that cancer cells from a deadly type of human brain tumor called glioblastoma release tiny sacs containing proteins that traverse the brain-blood barrier and contain genetic material that could be used as biomarkers in new diagnostic tools and perhaps as new targets for treatments too.

Celprogen Inc., a Global leader in the Stem Cell Research and Therapeutics industry for development of stem cell technologies in regenerative medicine, today announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma. This in vivo model system has been validated within United States research facilities for testing novel drug candidates against Human Glioblastoma.